Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27629556 | 0.82 | SLC6A4 (0.32) | MEN1KMT2ACHRM5CHRM3SLC6A4 | |
| SCHEMBL13419180 | 0.78 | KDM4E (0.37) | MEN1KMT2ACHRM5CHRM3SLC6A4 | |
| SCHEMBL2551138 | 0.78 | KDM4E (0.37) | MEN1KMT2ACHRM5CHRM3SLC6A4 | |
| SCHEMBL3534793 | 0.78 | KDM4E (0.37) | MEN1KMT2ACHRM5CHRM3SLC6A4 | |
| SCHEMBL10379099 | 0.77 | — | — | |
| Ammonia Solution, Strong SCHEMBL10987919 | 0.76 | KDM4E (0.36) | MEN1KMT2ACHRM5CHRM3SLC6A4 | |
| SCHEMBL20569862 | 0.76 | HRH3 (0.37) | MEN1KMT2ACHRM5CHRM3SLC6A4 | |
| SCHEMBL10305702 | 0.76 | MEN1 (0.33) | MEN1KMT2ACHRM5CHRM3SLC6A4 | |
| SCHEMBL5197504 | 0.76 | MEN1 (0.33) | MEN1KMT2ACHRM5CHRM3SLC6A4 | |
| SCHEMBL15471 | 0.76 | HRH3 (0.37) | MEN1KMT2ACHRM5CHRM3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3750894-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2024-04-03 | — | — | EP | claimed |
| EP-3590941-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | claimed |
| EP-3750893-B1 | DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-04-19 | — | — | EP | claimed |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2021-04-20 | — | — | US | claimed |
| CN-111788207-B | Dioxane quinoline compound and preparation method and application thereof | 北京赛特明强医药科技有限公司 | 2021-03-23 | — | — | CN | claimed |
| CN-111757885-B | Urea-substituted aromatic ring-connected dioxane quinoline compound and preparation method and application thereof | 北京赛特明强医药科技有限公司 | 2021-01-29 | — | — | CN | claimed |
| US-20200399285-A1 | DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF | ACCSALUS BIOSCIENCES LIMITED (VG) | 2020-12-24 | — | — | US | claimed |
| US-20200399284-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2020-12-24 | — | — | US | claimed |
| EP-3750893-A1 | DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2020-12-16 | — | — | EP | claimed |
| EP-3750894-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2020-12-16 | — | — | EP | claimed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2004005279-A2 | SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-15 | — | — | WO | claimed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| EP-1358161-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Amgen Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | claimed |
| CN-1418112-A | Peptidase cleavable, targeted antineoplastic agents and therapeutic uses thereof | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-05-14 | — | — | CN | claimed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | claimed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | claimed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | claimed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399284-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF | RET, BRAF, RAF1 | MEN1 3338/4885KMT2A 754/4885CHRM5 3583/4885 |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BRAF, RAF1, ARAF | MEN1 3672/4885KMT2A 1657/4885CHRM5 4394/4885 |
| US-20200399285-A1 | DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF | KDR, MET, ABL1 | MEN1 360/4885KMT2A 335/4885CHRM5 2085/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | MEN1 2237/4885KMT2A 1457/4885CHRM5 2342/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | MEN1 664/4885KMT2A 1259/4885CHRM5 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.